Open AccessIncreased Dose of Lopinavir/Ritonavir Compensates for Efavirenz-Induced Drug-Drug Interaction in HIV-1-Infected Children
Author(s) -
Alina S. Bergshoeff,
Pieter L. A. Fraaij,
Jennifer Ndagijimana,
Gwenda Verweel,
Nico G. Hartwig,
Tim Niehues,
Ronald de Groot,
David M. Burger
Publication year - 2005
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/01.qai.0000155203.89350.85
Subject(s) - efavirenz , lopinavir , ritonavir , lopinavir/ritonavir , nevirapine , pharmacokinetics , pharmacology , cmin , reverse transcriptase inhibitor , medicine , interquartile range , cmax , virology , viral load , human immunodeficiency virus (hiv) , antiretroviral therapy
Nucleoside reverse transcriptase inhibitor-sparing regimens have not yet been systematically evaluated in children. The nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz lower plasma levels of protease inhibitors in adults and children. Therefore, coadministration of lopinavir/ritonavir with nevirapine and efavirenz necessitates a 30% increase in the dose of lopinavir/ritonavir in adults. In children, the extent of the pharmacokinetic interaction between efavirenz and lopinavir/ritonavir has not yet been studied.